Sovaprevir : Wikipedia, the free encyclopedia

Sovaprevir

Chemical compound

None

Legal statusLegal status

Investigational

Identifiers

IUPAC name

(4R)-N-{(1R,2S)-1-[(Cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropyl}-1-{(2S)-3,3-dimethyl-2-[2-oxo-2-(1-piperidinyl)ethyl]butanoyl}-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolinamide

CAS Number

1001667-23-7

PubChem CID

53362096

ChemSpider

28529313

UNII

2ND9V3MN6O

KEGG

D10166

ChEMBL

ChEMBL2105750

NIAID ChemDB

491583

CompTox Dashboard (EPA)

DTXSID00142994

Chemical and physical dataFormulaC₄₃H₅₃N₅O₈SMolar mass799.98 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

CC(C)(C)[C@H](CC(=O)N1CCCCC1)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=CC(=NC6=C5C=CC(=C6)OC)C7=CC=CC=C7

InChI

InChI=1S/C43H53N5O8S/c1-6-28-25-43(28,41(52)46-57(53,54)31-16-17-31)45-39(50)36-22-30(26-48(36)40(51)33(42(2,3)4)23-38(49)47-19-11-8-12-20-47)56-37-24-34(27-13-9-7-10-14-27)44-35-21-29(55-5)15-18-32(35)37/h6-7,9-10,13-15,18,21,24,28,30-31,33,36H,1,8,11-12,16-17,19-20,22-23,25-26H2,2-5H3,(H,45,50)(H,46,52)/t28-,30-,33-,36+,43-/m1/s1
Key:MHFMTUBUVQZIRE-WINRQGAFSA-N

Sovaprevir (codenamed ACH-1625) is an experimental drug designed to treat the hepatitis C virus. It is under development by Achillion Pharmaceuticals. It acts as a NS3/4A inhibitor.^[1] Sovaprevir received fast track status from the U.S. Food and Drug Administration in 2012.^[2]

References

^ De Clercq E (June 2014). "Current race in the development of DAAs (direct-acting antivirals) against HCV". Biochemical Pharmacology. 89 (4): 441–52. doi:10.1016/j.bcp.2014.04.005. PMID 24735613.
^ "Sovaprevir HCV NS3/4A Protease Inhibitor". Achillion.

External links

Achillion Provides Pipeline Update

RNA virus antivirals (primarily J05, also S01AD and D06BB)

Hepatitis C

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir^‡ Ciluprevir^§ Danoprevir^† Faldaprevir^‡ Glecaprevir Grazoprevir Narlaprevir Paritaprevir Simeprevir Sovaprevir^† Telaprevir^‡ Vaniprevir Vedroprevir^§ Voxilaprevir
NS5A inhibitors (–asvir)	Coblopasvir Daclatasvir^# Elbasvir Ledipasvir Odalasvir^† Ombitasvir Pibrentasvir Ravidasvir^† Ruzasvir^† Samatasvir^† Velpatasvir
NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir^† Bemnifosbuvir^† Dasabuvir^# Deleobuvir^§ Filibuvir^§ GS-6620^§ IDX-184^§ Setrobuvir^§ Sofosbuvir^# Tegobuvir^§ TMC-647055^§ Radalbuvir^† Uprifosbuvir^†
Combination drugs	Elbasvir/grazoprevir Glecaprevir/pibrentasvir Ledipasvir/sofosbuvir^# Ombitasvir/paritaprevir/ritonavir^# Sofosbuvir/daclatasvir Sofosbuvir/velpatasvir^# Sofosbuvir/velpatasvir/voxilaprevir

Hepatitis D

Bulevirtide

Picornavirus

viral entry: Pleconaril^†

Anti-influenza agents

neuraminidase inhibitors/release phase (Oseltamivir^#
Zanamivir
Peramivir, Laninamivir^†)

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a^# Peginterferon alfa-2b^#
3CL protease inhibitors (–trelvir)	Ensitrelvir^† Lufotrelvir Nirmatrelvir^† (+ritonavir)^† Rupintrivir Simnotrelvir (+ritonavir^†)
RNA pol inhibitors	CMX521^§ Deuremidevir^† Favipiravir Galidesivir^† GS-441524^§ Remdesivir MK-608^§ Mericitabine^† Molnupiravir NITD008^§ Ribavirin^# Taribavirin^† Triazavirin Valopicitabine^†
Multiple/Unknown/Other	EICAR^§ Merimepodib^§ Moroxydine Presatovir^†